Sequence-dependent cross-resistance of combined radiotherapy plus BRAF(V600E) inhibition in melanoma

Journal article


Publication Details

Author(s): Shannan B, Matschke J, Chauvistre H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Varaljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Gruenewald TGP, Schadendorf D, Jendrossek , Roesch A
Journal: European journal of cancer
Publication year: 2019
Volume: 109
Pages range: 137-153
ISSN: 0959-8049


Abstract

Introduction: Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common.


FAU Authors / FAU Editors

Heinzerling, Lucie Prof. Dr.
Hautklinik


External institutions with authors

Albert-Ludwigs-Universität Freiburg
Deutsches Krebsforschungszentrum (DKFZ)
Hannover Medical School / Medizinische Hochschule Hannover (MHH)
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Klinikum der Universität München (Großhadern und Innenstadt)
Ludwig-Maximilians-Universität (LMU)
Technische Universität Dresden
Universität Duisburg-Essen (UDE)
Universitätsklinikum Tübingen
Universität zu Lübeck


How to cite

APA:
Shannan, B., Matschke, J., Chauvistre, H., Vogel, F., Klein, D., Meier, F.,... Roesch, A. (2019). Sequence-dependent cross-resistance of combined radiotherapy plus BRAF(V600E) inhibition in melanoma. European journal of cancer, 109, 137-153. https://dx.doi.org/10.1016/j.ejca.2018.12.024

MLA:
Shannan, B., et al. "Sequence-dependent cross-resistance of combined radiotherapy plus BRAF(V600E) inhibition in melanoma." European journal of cancer 109 (2019): 137-153.

BibTeX: 

Last updated on 2019-06-03 at 10:08